The framework the new FDA leaders laid out on Tuesday raised small and big questions about the regulatory process, vaccine access, and medical ethics.

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula,

The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the virus, and those older than age 65.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

Peter A. McCullough, a former cardiologist who promoted unproven treatments like ivermectin and hydroxychloroquine at the height of the pandemic, posted a video to Instagram claiming that Biden’s cancer was “turbo cancer.”

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.